CJD Tissue/Cell Donor Draft Guidance Is Topic Of Upcoming TSE Meeting
This article was originally published in The Gray Sheet
Executive Summary
FDA is requesting data to assess the impact of recommendations to reduce the risk of transmission of CJD and vCJD on the availability of human cells, tissues and cellular and tissue-based products (HCT/P)
You may also be interested in...
TSE Panel Comments On Tissue Decontamination Protocols, Pooled Samples
FDA should develop specific protocols for mitigating the transmission of Creutzfeld-Jakob disease and viral CJD in human cells, tissues and cellular and tissue-based products (HCT/Ps) for evaluation by the Transmissible Spongiform Encephalopathies Advisory Committee (TSEAC) at a future meeting, TSEAC voted June 26
TSE Panel Comments On Tissue Decontamination Protocols, Pooled Samples
FDA should develop specific protocols for mitigating the transmission of Creutzfeld-Jakob disease and viral CJD in human cells, tissues and cellular and tissue-based products (HCT/Ps) for evaluation by the Transmissible Spongiform Encephalopathies Advisory Committee (TSEAC) at a future meeting, TSEAC voted June 26
FDA Stands Firm As Canada Follows Britain, Japan In Dura Mater Suspension
Health Canada's suspension of the medical device licence for Tutogen's Tutoplast Dura represents a virtual ban on the importation and sale of all human dura mater products throughout the country